Beta Bionics, Inc.
NASDAQ:BBNXMedical - Equipment & Services
+$0.42 today
- Market cap
- $644.70M
- Beta
- 3.39
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.50
Volume 1.38M
Average 0.99M
BBNX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Beta Bionics, Inc.NASDAQ: BBNX
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q1 FY2026 selling, general & admin of $30.35M rose 51.6% year over year, behind the +61.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 21.7% from the prior quarter. Over 3 fiscal years it compounded at +40.3% a year.
Context
- Selling, general & admin amounted to 92.2% of revenue in FY2025, up 7.8 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 10 analysts of $5.99B (+6382.3%) for the fiscal year ending Dec 2026, a step up from the +68.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $30.35M+21.7% QoQ
- Last fiscal yearDec 2025
- $92.43M+68.2% YoY
- LTMMar 2026
- $102.76M+61.1% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 92.43M USD
- Year-over-year change
- +68.2%
- 3-year CAGR
- +40.3%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 92.43M | +68.2% |
| FY2024 | 2024-12-31 | 54.96M | +126.9% |
| FY2023 | 2023-12-31 | 24.22M | -27.7% |
| FY2022 | 2022-12-31 | 33.5M | — |
Selling, General & Admin vs competitors
How BBNX compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +61.1% is the 2nd highest of 7, against a peer median of +14.2%.
- Selling, general & admin amounts to 93.2% of revenue for BBNX, versus a peer median of 40.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 64.84B DKK | -9.7% | +11.5% | 19.7% | |
| LTM Jun 2026 | $1.36B USD | +7.0% | +8.6% | 27.4% | |
| LTM Jun 2026 | $1.31B USD | +29.1% | +25.6% | 42.9% | |
MMEDMiniMed Group, Inc. Common Stock | LTM Jul 2026 | $1.24B USD | — | +7.2% | 38.4% |
| LTM Mar 2026 | $437.36M USD | +5.8% | +9.0% | 42.6% | |
| LTM Mar 2026 | $173.21M USD | +78.5% | +16.4% | 48.0% | |
| LTM Mar 2026 | $102.76M USD | +61.1% | +40.3% | 93.2% | |
| LTM Mar 2026 | $8.48M USD | +21.4% | -17.7% | — | |
| Peer median (excluding BBNX) | — | +14.2% | +9.0% | 40.5% | |
Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 179K | 12M | 65.12M | 100.25M |
| Cost of Revenue | 0 | 5.69M | 29.24M | 44.71M |
| Gross Profit | 179K | 6.31M | 35.89M | 55.54M |
| Gross Margin | 100.0% | 52.6% | 55.1% | 55.4% |
| Research & Development | 31.43M | 17.94M | 26.18M | 34.79M |
| Selling, General & Admin | 33.5M | 24.22M | 54.96M | 92.43M |
| Operating Expenses | 66.02M | 42.16M | 81.14M | 127.22M |
| Depreciation & Amortization | 1.35M | 1.23M | 1.15M | 2.88M |
| EBITDA | (63.4M) | (42.87M) | (53.61M) | (70.32M) |
| EBITDA Margin | -35418.4% | -357.4% | -82.3% | -70.1% |
| Operating Income | (65.84M) | (35.85M) | (45.25M) | (71.68M) |
| Operating Margin | -36784.4% | -298.9% | -69.5% | -71.5% |
| Interest Income | 196K | 1.78M | 3.91M | 10.93M |
| Interest Expense | 14K | 0 | 0 | 0 |
| Other Income / Expenses | 1.09M | (8.25M) | (9.51M) | (1.52M) |
| Income Before Tax | (64.75M) | (44.1M) | (54.76M) | (73.2M) |
| Pre-Tax Margin | -36173.7% | -367.6% | -84.1% | -73.0% |
| Income Tax Expense | 0 | 0 | 0 | 1K |
| Net Income | (64.75M) | (44.1M) | (54.76M) | (73.2M) |
| Net Margin | -36173.7% | -367.6% | -84.1% | -73.0% |
| EPS (Basic) | (12.96) | (8.31) | (8.60) | (1.81) |
| EPS (Diluted) | (12.96) | (8.31) | (8.60) | (1.81) |
| Weighted Avg Shares | 5M | 5.3M | 6.37M | 40.53M |
| Weighted Avg Shares (Diluted) | 5M | 5.3M | 6.37M | 40.53M |
Beta Bionics, Inc.
NASDAQ:BBNX
Intrinsic Alpha fair value
Locked
Current Price
$14.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.